Verrica Pharmaceuticals Inc. (NASDAQ: VRCA) reported Q3 EPS of $0.13, $0.21 better than the analyst estimate of ($0.08). Revenue for the quarter came in at $14.3 million versus the consensus estimate of $5.34 million.

For earnings history and earnings-related data on Verrica Pharmaceuticals Inc. (VRCA) click here.